baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Morgan Stanley Discount Zert GILD.../ DE000ME57S36 /

6/18/2024 8:45:55 PM	Chg.0.00	Bid10:00:34 PM	Ask10:00:34 PM	Underlying	Strike price	Expiration date	Option type
48.03EUR	0.00%	- Bid Size: -	- Ask Size: -	Gilead Sciences Inc	- USD	9/27/2024	Call

GlobeNewswire 6/18 Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation C...

GlobeNewswire 6/17 Assembly Biosciences Announces $12.6 Million in Equity Financings

GlobeNewswire 6/10 Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus He...

GlobeNewswire 5/22 Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congres...

GlobeNewswire 5/14 Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

GlobeNewswire 5/9 MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim ...

GlobeNewswire 5/9 HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire 5/8 Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

GlobeNewswire 5/8 Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

GlobeNewswire 4/29 Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...

GlobeNewswire 4/19 ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies...

GlobeNewswire 4/10 Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...

GlobeNewswire 4/3 Opthea Appoints Sujal Shah to the Board of Directors

GlobeNewswire 4/2 Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

GlobeNewswire 4/2 Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

GlobeNewswire 4/1 Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Fin...

GlobeNewswire 3/28 Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlight...

GlobeNewswire 3/28 Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

GlobeNewswire 3/28 Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

GlobeNewswire 3/22 HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highl...

GlobeNewswire 3/18 CIO Celebrates Innovations in Business Technology with 2024 CIO 100 & Hall of Fame Awards

GlobeNewswire 3/11 Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase...

GlobeNewswire 2/29 BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay The...

GlobeNewswire 2/29 Abingworth Announces a Strategic Development Financing Agreement with Gilead Sciences; Establishes J...

GlobeNewswire 2/28 CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corpo...

Morgan Stanley Discount Zert GILD.../ DE000ME57S36 /

If you wish to receive reply to your feedback, please provide your email address.